DEA Compliance: Navigating Digital Identity Rules

Excluded from normalized aggregate trends after staff review: 3056 posts were attributed to March 2026; 671 shared March 14, 2026. The preceding six-month median was 13.5 posts.

Review evidence: 3,056 posts in March 2026; 671 shared March 14, 2026; preceding six-month median 13.5. Reviewed August 9, 2026.

This company's pages remain public, but its content is excluded from normalized aggregate trends. Unfiltered raw trends and advanced filtering are available to Accelerate and Lead accounts.

The Drug Enforcement Administration (DEA) plays a pivotal role in regulating the handling of controlled substances, particularly as telehealth and digital prescribing become more prevalent, posing new compliance challenges. The DEA's interim final rule on electronic prescribing of controlled substances (EPCS) mandates robust identity proofing and two-factor authentication (2FA) for prescribers to prevent fraud and diversion, emphasizing the need for high assurance in digital identity verification. Telehealth providers must comply with the same regulations as in-person practices, including identity proofing and adhering to specific criteria for establishing patient-physician relationships, with special considerations for interstate prescribing. Strong digital identity verification is crucial not only for compliance but also for safeguarding patient safety by reducing the risk of fraudulent prescriptions. Solutions like Didit's digital identity platform help organizations meet DEA compliance requirements through secure identity verification, 2FA integration, fraud detection, and workflow orchestration, ensuring that healthcare providers can protect legitimate patients while adhering to evolving regulatory standards.

Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.